(SOLS) Solstice Advanced Materials - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NASDAQ (USA) | Market Cap: 12.606m USD | Total Return: 69.1% in 12m
Avg Turnover: 171M
Rev. Trend: 100.0%
Warnings
Below Avwap Earnings
Tailwinds
Leader
Solstice Advanced Materials, Inc. (NASDAQ: SOLS) is a New Jersey-based specialty chemicals provider focused on low global warming potential (LGWP) solutions and advanced electronic materials. The company operates through two primary segments: Refrigerants & Applied Solutions (RAS) and Electronic & Specialty Materials (ESM). Its RAS division manufactures sustainable refrigerants and aerosol propellants under brands such as Solstice and Genetron, while the ESM division supplies high-purity chemicals and high-strength fibers for the semiconductor and defense sectors.
The specialty chemicals sector is characterized by high barriers to entry due to complex regulatory requirements and the intensive research and development needed to replace legacy high-GWP fluids. By producing lightweight fibers and sputtering targets, the company integrates directly into the aerospace and semiconductor supply chains, where material purity is a critical performance driver. For a more granular look at the companys competitive positioning, you may find additional insights on ValueRay.
Incorporated in 2025, the company maintains a portfolio of established brands, including Spectra, Fluka, and Aclar. Its business model relies on the global transition toward environmentally compliant materials and the increasing demand for high-performance chemical inputs in the technology and pharmaceutical industries.
- Transition to low global warming potential refrigerants drives revenue in RAS segment
- Global semiconductor demand fluctuations impact sputtering target sales and ESM margins
- Environmental regulations accelerate adoption of Solstice brand blowing agents and solvents
- Defense spending levels dictate demand for high-strength Spectra fiber applications
- Raw material cost volatility influences overall specialty chemical manufacturing profitability
| Net Income: 206.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -6.99 > 1.0 |
| NWC/Revenue: 18.69% < 20% (prev 26.99%; Δ -8.31% < -1%) |
| CFO/TA 0.09 > 3% & CFO 499.0m > Net Income 206.5m |
| Net Debt (1.89b) to EBITDA (910.5m): 2.07 < 3 |
| Current Ratio: 1.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (159.3m) vs 12m ago 0.37% < -2% |
| Gross Margin: 31.31% > 18% (prev 0.35%; Δ 3.10k% > 0.5%) |
| Asset Turnover: 69.83% > 50% (prev 68.90%; Δ 0.92% > 0%) |
| Interest Coverage Ratio: 12.42 > 6 (EBITDA TTM 910.5m / Interest Expense TTM 55.5m) |
| A: 0.13 (Total Current Assets 2.44b - Total Current Liabilities 1.71b) / Total Assets 5.75b |
| B: 0.02 (Retained Earnings 113.0m / Total Assets 5.75b) |
| C: 0.12 (EBIT TTM 689.5m / Avg Total Assets 5.60b) |
| D: -0.00 (Book Value of Equity -13.0m / Total Liabilities 4.28b) |
| Altman-Z'' = 1.72 = BBB |
| DSRI: 1.38 (Receivables 943.0m/659.0m, Revenue 3.91b/3.76b) |
| GMI: 1.11 (GM 31.31% / 34.69%) |
| AQI: 0.83 (AQ_t 0.21 / AQ_t-1 0.26) |
| SGI: 1.04 (Revenue 3.91b / 3.76b) |
| TATA: -0.05 (NI 206.5m - CFO 499.0m) / TA 5.75b) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 79.38 with a total of 2,830,219 shares traded.
Over the past week, the price has changed by -3.94%,
over one month by +0.52%,
over three months by +4.19% and
over the past year by +69.09%.
Solstice Advanced Materials has no consensus analysts rating.
P/E Forward = 32.7869
P/S = 3.37
P/B = 9.0281
P/EG = 1.0878
Revenue TTM = 3.91b USD
EBIT TTM = 689.5m USD
EBITDA TTM = 910.5m USD
Long Term Debt = 1.98b USD (from longTermDebt, last quarter)
Short Term Debt = 351.0m USD (from shortTermDebt, last quarter)
Debt = 2.53b USD (from shortLongTermDebtTotal, last quarter) + Leases 114.0m
Net Debt = 1.89b USD (calculated: Debt 2.53b - CCE 642.0m)
Enterprise Value = 14.5b USD (12.6b + Debt 2.53b - CCE 642.0m)
Interest Coverage Ratio = 12.42 (Ebit TTM 689.5m / Interest Expense TTM 55.5m)
EV/FCF = 102.8x (Enterprise Value 14.5b / FCF TTM 141.0m)
FCF Yield = 0.97% (FCF TTM 141.0m / Enterprise Value 14.5b)
FCF Margin = 3.60% (FCF TTM 141.0m / Revenue TTM 3.91b)
Net Margin = 5.28% (Net Income TTM 206.5m / Revenue TTM 3.91b)
Gross Margin = 31.31% ((Revenue TTM 3.91b - Cost of Revenue TTM 2.69b) / Revenue TTM)
Gross Margin QoQ = 31.89% (prev 26.14%)
Tobins Q-Ratio = 2.52 (Enterprise Value 14.5b / Total Assets 5.75b)
Interest Expense / Debt = 2.19% (Interest Expense 55.5m / Debt 2.53b)
Taxrate = 22.79% (31.0m / 136.0m)
NOPAT = 532.3m (EBIT 689.5m * (1 - 22.79%))
Current Ratio = 1.43 (Total Current Assets 2.44b / Total Current Liabilities 1.71b)
Debt / Equity = 1.70 (Debt 2.53b / totalStockholderEquity, last quarter 1.49b)
Debt / EBITDA = 2.07 (Net Debt 1.89b / EBITDA 910.5m)
Debt / FCF = 13.39 (Net Debt 1.89b / FCF TTM 141.0m)
Total Stockholder Equity = 1.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.69% (Net Income 206.5m / Total Assets 5.75b)
RoE = 11.24% (Net Income TTM 206.5m / Total Stockholder Equity 1.84b)
RoCE = 18.06% (EBIT 689.5m / Capital Employed (Equity 1.84b + L.T.Debt 1.98b))
RoIC = 12.12% (NOPAT 532.3m / Invested Capital 4.39b)
WACC = 5.80% (E(12.6b)/V(15.1b) * Re(6.62%) + D(2.53b)/V(15.1b) * Rd(2.19%) * (1-Tc(0.23)))
Discount Rate = 6.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.25 | Cagr: 0.24%
[DCF] Terminal Value 73.10% ; FCFF base≈290.8m ; Y1≈255.0m ; Y5≈206.0m
[DCF] Fair Price = 8.94 (EV 3.31b - Net Debt 1.89b = Equity 1.42b / Shares 158.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.98 | Revenue CAGR: 3.20% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.77 | Chg30d=-0.41% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.68 | Chg30d=-2.76% | Revisions=-14% | Analysts=4
EPS current Year (2026-12-31): EPS=2.63 | Chg30d=-1.43% | Revisions=-11% | GrowthEPS=+76.3% | GrowthRev=+4.8%
EPS next Year (2027-12-31): EPS=3.13 | Chg30d=-0.57% | Revisions=-11% | GrowthEPS=+19.1% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: -14%